This continuing medical education activity is provided by
This activity is supported by an educational grant from ViiV Healthcare.
Paul E. Sax, MD
Division of Infectious Diseases
Brigham and Women's Hospital Professor of Medicine
Harvard Medical School
Advisory Board: AbbVie, Bristol-Myers Squibb, GlaxoSmithKline/ViiV, Gilead, Janssen, Merck
Investigator: Bristol-Myers Squibb, GlaxoSmithKline/ViiV, Gilead, Merck
Faculty: Karam Mounzer, MD
Medical Director of Philadelphia FIGHT
Clinical Associate Professor of Medicine
The Perelman School of Medicine at the University of Pennsylvania
Advisory Board: Gilead, Janssen, Merck, ViiV
Investigator: Gilead, Janssen, Merck, ViiV
Consultant: Gilead, Janssen, Merck, ViiV
Speakers Bureau: CCO, Gilead, Janssen, Simply Speaking
Rebecca A. Clark, MD
No relevant financial relationships to disclose.
National Jewish Health and Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at National Jewish Health, Office of Professional Education, and Vindico Medical Education, Office of Medical Affairs and Compliance.
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, authors, and reviewers involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience prior to viewing content.
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
National Jewish Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, March 31, 2016 to March 31, 2017.
How to Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must reference the objectives, answer the pretest questions, watch, read, and listen to the content, complete the CME posttest, and then fill in the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, National Jewish Health will issue an AMA PRA Category 1 Credits™ Certificate.
Overview: With the availability of highly effective antiretroviral agents and combinations, treatment-experienced HIV patients with extensive drug resistance now have multiple options for suppressive therapy. However, advances in treatment and management also create new challenges for clinicians who must be knowledgeable about the expanding treatment armamentarium, interpretation of various resistance tests, as well as complex issues of pharmacokinetics and drug interactions. This interactive, case-based activity will address the complexity of optimizing therapeutic regimens for treatment-experienced patients with drug-resistant HIV infection. Expert commentaries offered by faculty will provide insight into the selection of antiretroviral therapy for treatment-experienced patients, individualizing therapy based on antiretroviral history with known or suspected resistance, and interactions with concomitant medications.
Target Audience: The intended audience for the activity is infectious disease specialists, HIV treaters, and other health care professionals involved in the treatment of patients with HIV.
Upon successful completion of the educational series, participants should be better able to:
- Utilize evidence-based guidelines as well as clinical knowledge of available and emerging therapies to develop initial HIV treatment regimens based on individual patient characteristics.
- Review the cost-effectiveness of available HIV therapies.
- Develop simplified HIV treatment regimens that reflect patient preference and increase adherence.
- Differentiate available and emerging HIV treatment regimens based on resistance profile.
- Apply knowledge of effective switch strategies and NRTI-sparing regimens that have demonstrated a low risk of virological failure in patients who would benefit from treatment alteration.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2016 Vindico Medical Education. All rights reserved.
No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of National Jewish Health and Vindico Medical Education continuing education activities does not necessarily reflect the views and opinions of National Jewish Health and Vindico Medical Education. Neither National Jewish Health, nor Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Contact us at: